Soluble Programmed Death 1 (sPD1) is a Diagnostic Biomarker of ILD in Patients With Rheumatoid Arthritis Disease
NCT05105230 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 66
Last updated 2022-01-12
Summary
1. Evaluate the levels of serum (sPD1) in RA patients with ILD and those without.
2. Detect subclinical RA-ILD for early diagnosis and management of this devastating manifestation of RA
Conditions
Interventions
- DIAGNOSTIC_TEST
-
soluble programmed death 1biomarker
soluble programmed death 1biomarker
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 16 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-01
- Primary Completion
- 2023-04-01
- Completion
- 2023-08-01
More Related Trials
-
IL-6, IL-12, IL-15 and IL-23 Expression Levels in Rheumatoid Arthritis Patients
NCT06558305 ·Status: NOT_YET_RECRUITING
-
Clinical Disease Activity and Modulation of Synovial Lymphoid Structures and B Cell Function in Rheumatoid Arthritis
NCT02528292 ·Status: UNKNOWN
-
Clinical Study of Single Dose IL-6R mAb Injection in RA Patients
NCT05232396 ·Status: COMPLETED ·Phase: PHASE1
-
RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis
NCT03016260 ·Status: TERMINATED
-
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
NCT01604343 ·Status: COMPLETED ·Phase: PHASE3
-
Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis
NCT01443364 ·Status: COMPLETED ·Phase: PHASE4
-
The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis
NCT05290363 ·Status: RECRUITING ·Phase: NA
-
Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients
NCT01559103 ·Status: TERMINATED ·Phase: PHASE1
-
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
NCT02451748 ·Status: COMPLETED ·Phase: PHASE4
-
IL17 Rate and Spondyloarthritis
NCT05592574 ·Status: RECRUITING
-
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
NCT00661661 ·Status: COMPLETED ·Phase: PHASE3
-
Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis
NCT01590966 ·Status: COMPLETED ·Phase: PHASE3
-
Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker
NCT01072058 ·Status: UNKNOWN ·Phase: PHASE4
-
Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003
NCT01856309 ·Status: COMPLETED ·Phase: PHASE3
-
Tapering of Biologics in Inflammatory Arthritis Patients in Remission
NCT04429776 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
NCT01060098 ·Status: COMPLETED
-
Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis
NCT02404558 ·Status: COMPLETED ·Phase: PHASE1
-
Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis
NCT01593332 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
NCT01557348 ·Status: COMPLETED
-
Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis
NCT06933134 ·Status: RECRUITING
-
Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis
NCT00545454 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
NCT01606761 ·Status: COMPLETED ·Phase: PHASE3
-
The Role of Microbiome on Biological Therapy Efficacy in axSpA and RA
NCT04973787 ·Status: UNKNOWN
-
Lysophosphatidic Acid / Autotaxin Axis in Rheumatoid Lung Disease
NCT04284735 ·Status: UNKNOWN ·Phase: NA
-
Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants
NCT04426279 ·Status: TERMINATED